Last updated 2026-06-18
- Raised $212M funding round, Nov 2025
- Raised $8M funding round, Sep 2017
- Raised $7M funding round, May 2014
Total raised
$286.9M
Last: 2025-11
Stage
Public
Founded
2005
Headcount
35
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming. The company intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis, COVID-19, and other indications. The company's most advanced product candidate, Allocetra, was developed for the reprogramming of diseased macrophages in patients with sepsis or COVID-19, and has demonstrated positive safety, tolerability, and efficacy in several clinical trials. In March 2019, the company announced the completion of its merger with Tel Aviv-headquartered Bioblast Pharma. Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was renamed Enlivex Therapeutics.
Funding history · 9 rounds · $286.9M total
2025-11
$212.0M
2021-05
Grant
$1.1M
2020-04
Grant
$1.5M
2019-05
Grant
$1.1M
2019-04
Grant
$1.0M
2017-09
2014-05
Date unknown
Grant
$1.2M
Date unknown
$15.0M
Q&A
- What is Enlivex Therapeutics' primary focus?
- Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming for life-threatening diseases, including solid cancers, sepsis, and COVID-19.
- What is Enlivex Therapeutics' most advanced product candidate?
- Enlivex Therapeutics' most advanced product candidate is Allocetra, developed for reprogramming diseased macrophages in patients with sepsis or COVID-19.
- When was Enlivex Therapeutics founded?
- Enlivex Therapeutics was founded in September 2005.
- What was a significant corporate event for Enlivex Therapeutics in March 2019?
- In March 2019, Enlivex Therapeutics completed a merger with Bioblast Pharma, after which Enlivex became a subsidiary of the renamed Bioblast, now Enlivex Therapeutics.
- What is the employee count for Enlivex Therapeutics?
- Enlivex Therapeutics has 11-50 employees.
- What is the total amount raised by Enlivex Therapeutics?
- Enlivex Therapeutics has raised a total of $286,900,000.
- When did Enlivex Therapeutics receive its most recent funding round?
- Enlivex Therapeutics received a funding round in November 2025 for $212,000,000.
- Which entity has provided multiple grants to Enlivex Therapeutics?
- The Israel Innovation Authority has provided multiple grants to Enlivex Therapeutics, including in April 2019, May 2019, April 2020, and May 2021.
Team · 1
Founder · Founder, Chief Scientific & Medical Officer
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcareProvidersPatients
Business model
B2B
Highlights
1 Patents
Tags
cell-therapyinflammatory-diseasescrohn-s-diseasepharmaceuticalscancerimmunologyimmunotherapypharma-companieschronic-patientspatientsautoimmune-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | enlivex.com |
|---|---|
| linkedin.com/company/19117645 | |
| YouTube | youtube.com/channel/UCGJI8b2YMny7Gxu3mMrQlPg |
Identifiers & details
| Former names | Tolarex |
|---|---|
| Founded | 2005-9 |
| Employees (exact) | 35 |
| Market cap | $174.2M |
| Status reason | Public on NASDAQ on Mar 2019;Public on TASE on Jul 2019; |
Radar intelligence
Patents
| EPO | 22 |
|---|
Web history (Wayback)
| Domain | enlivex.com |
|---|
Certificate / subdomain footprint
| Subdomains | 17 |
|---|